HVTN Conference - HIV Vaccine Trials Network

Presentations have been posted here for the benefit of our meeting attendees. If you've reached this page from our members' website, you can return to it by going to www.hvtn.org/members or clicking "Back" on your browser.

Wednesday May 21

STEP Updates

502 STEP Update, Susan Buchbinder
Phambili Update, Glenda Gray
HVTN Post-STEP Activities, Larry Corey
Network Evaluation Committee and Community Education Award Presentations

Inducing Immunological Memory by Vaccination and HIV Infection

Ad-5 Induced CD8 T Cells: Quantity and Quality, Surojit Sarkar
TLR Ligands Influence the Magnitude and Quality of T Cell Responses, Robert Seder
Homologous Ad5 Prime/Ad5 Boost Compared with Heterologous DNA prime/Ad5 Boost in HVTN 068, Steve DeRosa
The HVTN Experience with Modified Vaccinia Ankara, Marnie Elizaga

Non-Human Primates Research

A Beginner’s Guide to HIV/AIDS Research with Non Human Primates, Marta Marthas

Thursday May 22

How do we get Better T Cell Breadth in an HIV Immunogen

Epitope Specific Responses in Non Human Primates and The Relationship to Protection from NHP Challenge, David Watkins
A Computational Method to Increase Gene Expression, Harlan Robins
Approaches to Modifying the Ubiquitin Pathways, Steve Patterson
Designing Better Inserts, A Biometric Approach, Steve Self

Introduction to HIV Vaccinology and Immunology

Background on HIV vaccine science for laypeople, Gail Broder

The HVTN – Readdressing our Aims

Reshaping the Scientific Agenda of the HVTN, Jim Kublin
Can prior preclinical findings help direct future vaccine clinical trials?, Paul Goepfert
Post-STEP community input, willingness in Atlanta, Mark Mulligan

Protocol Implementation Funds (PIF)

Financial Administration and Protocol Implementation Funds (PIF), Larry Smith

Friday May 23

PAVE 100 Update, Scott Hammer

Print | HVTN Home